Skip to main content

Passage BIO, Inc.

PASG
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001787297

No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Passage BIO, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of PASG: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders102103+1
Shares44.6M42.1M−2.51M (−5.6%)
Value$558.8M$419.1M−$139.7M (−25.0%)

New holders (17)

Institutions that held Passage BIO, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to PASG in Q3 2021
InstitutionSharesValue% of portfolio
Woodline Partners LP321,791$3.21M0.05%
HRT Financial LP80,513$801.0K0.00%
ExodusPoint Capital Management, LP28,408$283.0K0.00%
Qube Research & Technologies Ltd23,113$230.0K0.00%
Gsa Capital Partners LLP21,979$219.0K0.02%
Algert Global LLC20,056$200.0K0.03%
Dynamic Technology Lab Private Ltd17,771$177.0K0.02%
Virginia Retirement Systems Et Al15,900$158.0K0.00%
Dimensional Fund Advisors LP14,608$145.0K0.00%
Jane Street Group, LLC11,399$114.0K0.00%
Pinz Capital Management, LP10,800$108.0K0.05%
The PNC Financial Services Group, Inc.1,000$10.0K0.00%
Koshinski Asset Management, Inc.300$2.99K0.00%
Quadrant Capital Group LLC180$2.00K0.00%
Parallel Advisors, LLC110$1.00K0.00%
TSFG, LLC100$1.00K0.00%
Ellevest, Inc.8$00.00%

Sold out (16)

Institutions that held Passage BIO, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.